文献速递前列腺增生与排尿功能障碍

每日低剂量他达拉非治疗膀胱过度活动症的疗效:一项随机、双盲、安慰剂对照试验

Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial.
PubMed 文献 · Urology · 2016-11-11

该随机双盲安慰剂对照试验纳入中国浙江省南部3个医疗中心的96例特发性膀胱过度活动症女性,随机接受每日低剂量他达拉非5 mg(n=48)或安慰剂(n=48)治疗3个月。他达拉非组在多个时间点的膀胱过度活动症症状评分、排尿次数、尿失禁和尿急发作均较安慰剂组和基线显著改善(P<.05),排尿量和总膀胱容量明显增加(P<.05)。结论认为每日低剂量他达拉非是治疗女性膀胱过度活动症有效且耐受良好的方法。

要点

  • 他达拉非组膀胱过度活动症症状评分较安慰剂组和基线显著下降(P<.05)。
  • 他达拉非组排尿量及总膀胱容量较安慰剂组明显增加(P<.05)。
  • 最大尿流率、残余尿量和排尿效率未见变化。

核心结论

  • 每日低剂量他达拉非是治疗女性膀胱过度活动症有效且耐受良好的方法。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,纳入中国浙江省南部3个医疗中心的96例特发性膀胱过度活动症女性,随机分为他达拉非5 mg组(n=48)和安慰剂组(n=48),治疗3个月。

主要发现

  • 他达拉非组膀胱过度活动症症状评分较安慰剂组和基线显著下降,排尿次数、尿失禁和尿急发作在治疗第4、6、8、10、12周及治疗后3个月均显著改善(P<.05)。
  • 他达拉非组排尿量和总膀胱容量明显增加(P<.05)。
  • 他达拉非组Indevus尿急严重程度量表从第4周至治疗后3个月下降(P<.05)。
  • 最大尿流率、残余尿量和排尿效率未见变化。
  • 所有不良症状均为轻至中度。

关键数值与推荐

  • 他达拉非组给药方案为每日低剂量他达拉非5 mg,治疗3个月。
  • 疗效评估指标包括Indevus尿急严重程度量表、膀胱过度活动症症状评分(Homma等,2006)及3天排尿日记(排尿次数、尿失禁、尿急发作)。
  • 尿流率检查和经腹超声用于测定最大尿流率、排尿量、残余尿量、总膀胱容量和排尿效率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of daily low-dose tadalafil therapy for overactive bladder (OAB) in women. PATIENTS AND METHODS: A total of 96 women with idiopathic OAB from 3 medical centers in the south of Zhejiang Province of China were randomly assigned to treatment with daily low-dose tadalafil (5 mg, n = 48) or placebo (n = 48) for 3 months. The Indevus Urgency Severity Scale, overactive bladder symptom score (Homma et al, 2006), and a 3-day micturition diary with frequency, incontinence, and urgency episodes were recorded and compared before the treatment, every 2 weeks following the treatment, and 3 months after the treatment. Uroflowmetry and transabdominal ultrasound were also conducted following the treatment to determine the maximum flow rate, voided volume, postvoid residual volume, total bladder capacity, and voiding efficiency. The patient's overall rating of improvement in symptoms was assessed as well. RESULTS: The overactive bladder symptom score significantly decreased, and the frequency, incontinence, and urgency episodes significantly improved in the tadalafil treatment group as compared with the placebo group and baselines at weeks 4, 6, 8, 10, and 12, as well as 3 months posttreatment (P <.05). In addition, voided volume and total bladder capacity obviously increased in the treatment group (P <.05). The Indevus Urgency Severity Scale decreased from week 4 to 3 months posttreatment in the treatment group (P <.05). No changes were found in the maximum flow rate, postvoid residual volume, and voiding efficiency. All adverse symptoms were mild to moderate. CONCLUSION: Daily low-dose tadalafil is a considerable, well-tolerated, and effective treatment for OAB in women.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Chen H, Wang F, Yu Z, et al. Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial. Urology. 2016. PMID: 27845219. doi:10.1016/j.urology.2016.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。